2020
DOI: 10.21203/rs.3.rs-32952/v2
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Novel anti-SARS-CoV-2 mechanisms of fusion broad range anti- infective protein ricin A chain mutant-pokeweed antiviral protein 1 (RTAM-PAP1) in silico

Abstract: A deadly pandemic named COVID-19 caused by a new coronavirus SARS- CoV-2 has emerged in 2019 and is still spreading globally at a dangerous pace. As of today, there are no proven vaccines, therapies or even strategies to fight off this virus. Here, we describe the in silico results of a novel broad range anti-infective fusion protein RTAM-PAP1 against the various key pro- teins of SARS-CoV-2 using the latest protein-ligand docking software. RTAM-PAP1 was compared against the SARS-CoV-2 B38 antibody, ricin A ch… Show more

Help me understand this report
View published versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2020
2020
2020
2020

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 20 publications
0
1
0
Order By: Relevance
“…In work that utilises various grid resources, including EGI and OSG, together with the European Open Science Cloud (EOSC) [87], Hassan et al have performed an in-silico docking comparison between human COVID-19 patient antibody (B38) and RTA-PAP fusion protein (ricin a chain-pokeweed antiviral protein) against targets (S-protein RBD, Spike trimer, and membrane-protein) in SARS-CoV-2 [88]. RTA-PAP, plant-derived N-glycosidase ribosomal-inactivating proteins (RIPs), is a fusion of ricin a chain -isolated from Ricinus communis -and pokeweed antiviral proteinisolated from Phytolacca Americana, which the same researchers had demonstrated to be anti-infective against Hepatitis B in prior work [89].…”
Section: Other Covid-19 Research On Gridsmentioning
confidence: 99%
“…In work that utilises various grid resources, including EGI and OSG, together with the European Open Science Cloud (EOSC) [87], Hassan et al have performed an in-silico docking comparison between human COVID-19 patient antibody (B38) and RTA-PAP fusion protein (ricin a chain-pokeweed antiviral protein) against targets (S-protein RBD, Spike trimer, and membrane-protein) in SARS-CoV-2 [88]. RTA-PAP, plant-derived N-glycosidase ribosomal-inactivating proteins (RIPs), is a fusion of ricin a chain -isolated from Ricinus communis -and pokeweed antiviral proteinisolated from Phytolacca Americana, which the same researchers had demonstrated to be anti-infective against Hepatitis B in prior work [89].…”
Section: Other Covid-19 Research On Gridsmentioning
confidence: 99%